| Strategy | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Expected Key Milestones |
|---|---|---|---|---|---|---|
| FcRn+ | ||||||
| Thyroid Eye Disease (TED) | spiriTED | Phase 2b topline data expected in H1 2025 | ||||
| Thyroid Eye Disease (TED) | Phase 3 expected to begin in H2 2024 | |||||
| Additional autoantibody-mediated diseases | Evaluation ongoing | |||||
| Cardiovascular Inflammation | ||||||
| Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 2 expected to begin in H1 2024
Phase 2 topline data expected in H1 2025 | |||||
| FcRn+ | |||
| Thyroid Eye Disease (TED) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
spiriTED | |||
| Expected Key Milestone: Phase 2b topline data expected in H1 2025 | |||
| FcRn+ | |||
| Thyroid Eye Disease (TED) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Phase 3 expected to begin in H2 2024 | |||
| FcRn+ | |||
| Additional autoantibody-mediated diseases | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Evaluation ongoing | |||
| Cardiovascular Inflammation | |||
| Atherosclerotic Cardiovascular Disease (ASCVD) | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Expected Key Milestone: Phase 2 expected to begin in H1 2024
Phase 2 topline data expected in H1 2025 | |||
Note: Hatched bars represent trials that have not yet commenced
As part of our FcRn+ strategy, our initial indication is Thyroid Eye Disease (TED), an autoimmune disease characterized by autoantibodies that target orbital fibroblasts and adipocytes in the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
For our cardiovascular inflammation strategy, we are focused on atherosclerotic cardiovascular disease (ASCVD). ASCVD is a leading cause of death globally and preventing major cardiovascular events (MACE) represents a significant goal to improve global health outcomes.
We continue to seek additional opportunities for TOUR006. We continue to identify indications where IL-6 inhibition has shown evidence of clinical benefit despite no formal industry-led development programs as well as indications where we could bring TOUR006’s differentiated profile forward, capitalizing on external de-risking events.
For more information about our expanded access policy, please view here.
